Critical characteristics for corticosteroid solution metered dose inhaler bioequivalence

Molecular Pharmaceutics

Volumn 9, Issue 3, 2012, Pages 563-569

  Grainger, C I ^a   Saunders, M ^b   Buttini, F ^c   Telford, R ^d   Merolla, L L ^e   Martin, G P ^a   Jones, S A ^a   Forbes, B ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Kuecept Ltd   (United Kingdom)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF BRADFORD   (United Kingdom)

^e UNILEVER RESEARCH   (United Kingdom)

Author keywords

aerosol deposition; aerosol formulation; airway epithelial cell; inhaled corticosteroids; pressurized metered dose inhalers

Indexed keywords

BECLOMETASONE DIPROPIONATE; GLYCEROL;

AIRFLOW; ARTICLE; BIOEQUIVALENCE; CELL CULTURE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG SOLUBILITY; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; METERED DOSE INHALER; PARTICLE SIZE; PHYSICAL CHEMISTRY; POROSITY; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; SCANNING ELECTRON MICROSCOPY; SOLID STATE;

ABSORPTION; ADRENAL CORTEX HORMONES; AEROSOLS; BECLOMETHASONE; CELL LINE; EPITHELIAL CELLS; HUMANS; METERED DOSE INHALERS;

EID: 84858040013     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200415g     Document Type: Article

References (31)

1. Meredith, P. Bioequivalence and other unresolved issues in generic drug substitution Clin. Ther. 2003, 25, 2875-2890 (Pubitemid 37510596)
2. Verbeek, R. K.; Kanfer, I.; Walker, R. B. Generic substitution: The use of medicinal products containing different salts and implications for safety and efficacy Eur. J. Pharm. Sci. 2006, 28, 1-6
3. Dolovich, M. B.; Dhand, R. Aerosol drug delivery: developments in device design and clinical use Lancet 2010, 10, 60926-9
4. Adams, W. P.; Ahrens, R. C.; Chen, M. L.; Christopher, D.; Chowdhury, B. A.; Conner, D. P.; Dalby, R.; Fitzgerald, K.; Hendeles, L.; Hickey, A. J.; Hochhaus, G.; Laube, B. L.; Lucas, P.; Lee, S. L.; Lyapustina, S.; Li, B.; O'Connor, D.; Parikh, N.; Parkins, D. A.; Peri, P.; Pitcairn, G. R.; Riebe, M.; Roy, P.; Shah, T.; Singh, G. J.; Sharp, S. S.; Suman, J. D.; Weda, M.; Woodcock, J.; Yu, L. Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPS): workshop summary report J. Aerosol Med. Pulm. Drug Delivery 2010, 23, 1-29
5. Newman, S. P.; Steed, K. P.; Hooper, G.; Jones, J. I.; Upchurch, F. C. Improved targeting of beclomethasone dipropionate (250 μg metered dose inhaler) to the lungs of asthmatics with the spacehaler Resp. Med. 1999, 93, 424-431 (Pubitemid 29265354)
6. Leach, C. L. Improved delivery of inhaled steroids to the large and small airways Respir. Med. 1998, 92 (Suppl. A) 3-8
7. Leach, C. L.; Davidson, P. J.; Hasselquist, B. E. Lung deposition of hydrofluoroalkane 134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone Chest 2002, 122, 510-516 (Pubitemid 35002128)
8. Woodcock, A.; Acerbi, D.; Poli, G. Modulite technology: pharmacodynamic and pharmacokinetic implications Respir. Med. 2002, 96 (Suppl. D) 9-15
9. Inmaculada, S.; Harrison, L.; Myhre, P.; Pierce, A.; Machacek, J.; Ekholm, B.; Wang, Z.; Cline, A.; Helget, A. Bioequivalence of press-and-breathe and breath-actuated inhalers of beclomethasone dipropinate extrafien aerosol Clin. Drug Invest. 2002, 22, 523-531
10. Steckel, H.; Muller, B. W. Metered dose inhaler formulations with beclomethasone-17,21-dipropionate using the ozone friendly propellant R 134a Eur. J. Pharm. Biopharm. 1998, 46, 77-83 (Pubitemid 29168538)
11. Labelle, M.; Pike, R. K.; Graham, S. J.; Ormsby, E. D.; Bogard, H. A. Metered dose inhalers I. Drug content and particle size distribution of beclomethasone dipropionate J. Pharm. Biomed. Anal. 1996, 14, 793-800 (Pubitemid 26194293)
12. Barnes, A. R.; Nash, S. Comparison of aerodynamic particle size from 250 g per dose beclomethasone dipropionate metered dose inhalers Int. J. Pharm. 1996, 130, 255-258 (Pubitemid 26276291)
13. Leach, C.; Colice, G. L.; Luskin, A. Particle size of inhaled corticosteroids: does it matter? J. Allergy Clin. Immunol. 2009, 124, S88-S93
14. Searle, J. P.; Harrison, L. I. Effect of changing the fine particle mass of inhaled beclomethasone diproprionate on intrapulmonary deposition and pharmacokinetics Respir. Med. 1998, 92 (Suppl. A) 9-15
15. Tashkin, D. P. Extrafine corticosteroid aerosols from hydrofluoroalkane-134a metered dose inhalers. Potential advantages and disadvantages Chest 1999, 115, 316-318 (Pubitemid 29083032)
16. Derom, E.; Pauwels, R. A. Pharmacokinetic and pharmacodynamic properties of inhaled betametasone dipropionate delivered via hydrofluoroalkane-containing devices Clin.Pharmacokinet. 2005, 815-836 (Pubitemid 41126930)
17. Usmani, O. S.; Biddiscombe, M. F.; Barnes, P. J. Regional lung deposition and bronchodilator response as a function of β agonist particle size Am. J. Respir. Crit. Care Med. 2005, 55, 851-867
18. Sadler, R. C.; Prime, D.; Burnell, P. K.; Martin, G. P.; Forbes, B. Integrated in vitro experimental modelling of inhaled drug delivery: deposition, dissolution, absorption J. Drug Delivery Sci. Technol. 2011, 21, 311-228
19. Grainger, C. I.; Greenwell, L. L.; Martin, G. P.; Forbes, B. The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa Eur. J. Pharm. Biopharm. 2009, 71, 318-324
20. Grainger, C. I.; Greenwell, L. L.; Lockley, D. J.; Martin, G. P.; Forbes, B. Culture of Calu-3 cells at the air-liquid interface provides a representative model of the airway epithelial barrier Pharm. Res. 2006, 23, 1482-1490 (Pubitemid 43993811)
21. Edwards, D. A.; Hanes, J.; Caponetti, G.; Hrkach, J.; BenJebria, A.; Eskew, M. L.; Mintzes, J.; Deaver, D.; Lotan, N.; Langer, R. Large porous particles for pulmonary drug delivery Science 1997, 276 (5320) 1868-1872
22. Freiwald, M.; Valotis, A.; Kirschbaum, A.; McClellan, M.; Murdter, T.; Fritz, P.; Friedel, G.; Thomas, M. Hogger P. Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model Respir. Res. 2005, 6, 21
23. Nachiengtung, N. Solid-state characterisation of beclomethasone dipropionate solvates and polymorphs; PhD thesis, Purdue University, 1999.
24. Smyth, H. D. C. The influence of variables on the performance of alternative propellant-driven metered dose inhalers Adv. Drug Delivery Rev. 2003, 55, 807-828 (Pubitemid 36776795)
25. Daley-Yates, P. T.; Parkins, D. A.; Thomas, M. J.; Gillett, B.; House, K. W.; Ortega, H. G. Pharmacokinetic, pharmacoduynamic, efficacy and safety data from two randomised, double blind studies in patients with asthma and an in vitro study comparing two dry powder inhalers delivering a combination of salmeterol 50 μg and fluticasone propionate 250 μg: implications for establishing bioequivalence of inhaled products Clin. Ther. 2009, 31, 370-385
26. Bérubé, K.; Aufderheide, M.; Breheny, D.; Combes, R.; Duffin, R.; Clothier; Forbes, B.; Gaça, M.; Gray, A.; Hall, I.; Kelly, M.; Lethem, M.; Liebsch, M.; Morello, L.; Morin, J.-P.; Seagrave, J.-C.; Swartz, M.; Tetley, T.; Umachandran, M. In vitro models of inhalation toxicity and disease-the report of a FRAME workshop ATLA, Altern. Lab. Anim. 2009, 37, 89-141
27. Cooney, D.; Kazantseva, A. J.; Hickey, A. J. Development of a size-dependent aerosol deposition model utilising human airway epithelial cells for evaluating aerosol drug delivery ATLA, Altern. Lab. Anim. 2004, 32, 581-590 (Pubitemid 40321537)
28. Lim, S. T.; Forbes, B.; Martin, G. P.; Brown, M. B. In vivo and in vitro characterization of novel microparticles based on hyaluronan and chitosan hydroglutamate AAPS PharmSciTech 2001, 2, 1-14
29. Bur, M.; Rothen-Rutishauser, B.; Huwer, H.; Lehr, C.-M. A novel cell compatible impingement system to study in vitro drug absorption from dry powder aerosol formulations Eur. J. Pharm. Biopharm 2009, 72, 350-357
30. Hill, M. R.; Vaughan, L. M. Effect of delivery mode on pharmacokinetics of inhaled drugs: experience with beclomethasone Respir. Drug Delivery 1998, 6, 53-60
31. Poli, G.; Acerbi, D. Comparison of the bioavailability and systemic effects of beclomethasone dipropionate suspension for nebulisation and beclomethasone dipropionate via a metered dose inhaler after single dose administration in healthy males Respir. Med. 2003, 97 (Suppl. B) 5-9